A simplified regimen of combined low-dose rituximab has better safety and efficacy than conventional therapy in patients with CIDP, a study found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback